casirivimab + imdevimab

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Regeneron Pharmaceuticals

Conditions

CoronavirusCovid19SARS-CoV-2

Phase 1

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

TerminatedNCT05081388

Regeneron PharmaceuticalsSARS-CoV-2

Start: 2021-11-08End: 2022-06-30Updated: 2025-10-28

Phase 2

ACTIV-2: A Study for Outpatients With COVID-19

CompletedNCT04518410

National Institute of Allergy and Infectious Diseases (NIAID)Coronavirus, Covid19

Start: 2020-08-19End: 2023-06-20Updated: 2024-08-02

Related Papers

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.

UNC Libraries2026-05-28

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution

Microbiology Spectrum2026-05-18

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19

UNC Libraries2025-02-05

Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection

UNC Libraries2025-02-05

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

UNC Libraries2025-02-05

Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

UNC Libraries2025-02-05

Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials

UNC Libraries2025-02-05

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

UNC Libraries2025-02-05

Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response

UNC Libraries2024-10-03

Variant-Specific Viral Kinetics in Acute COVID-19

UNC Libraries2024-09-01

Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

UNC Libraries2024-09-01

Immune Status and SARS-CoV-2 Viral Dynamics

UNC Libraries2024-09-01

Long COVID After Bamlanivimab Treatment

UNC Libraries2024-09-01

Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response

Pathogens and Immunity2024-08-212 citations

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial

The Journal of Infectious Diseases2024-07-181 citations

SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19

Clinical Infectious Diseases2024-07-172 citations

Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019

UNC Libraries2023-10-11

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.

2023-10-069 citations

One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.

2023-10-0114 citations

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

The Journal of Infectious Diseases2023-08-3112 citations

19 more papers not shown